Introducing Paliperidone Tablets by PharmAlliance International Labs Private Limited

Welcome to PharmAlliance International Labs, where our mission is to provide exceptional pharmaceutical solutions to enhance global health and well-being. Our Paliperidone Tablets represent a significant advancement in the management of schizophrenia and related psychotic disorders, offering patients a reliable treatment option backed by cutting-edge research and unwavering commitment to quality.

Drug Classification:

Paliperidone belongs to the class of atypical antipsychotics, renowned for their efficacy in treating psychosis. Acting as both a dopamine D2 and serotonin 5-HT2 receptor antagonist, Paliperidone modulates neurotransmitter activity in the brain, effectively alleviating symptoms of psychosis.

Formulations:

Paliperidone Tablets:

• Strength: Available in 3mg and 6mg tablets.
• Product Form: Oral tablets for convenient administration.
• Packing Specs: Each pack contains 29 tablets.

Indications:

Paliperidone Tablets are indicated for the treatment of the following conditions:

Schizophrenia: Effective for both acute exacerbations and maintenance therapy to prevent relapse.

Related Psychotic Disorders: Suitable for schizoaffective disorder and other psychotic disorders characterized by delusions, hallucinations, and disorganized thinking.

Usage:

For optimal efficacy, Paliperidone Tablets should be taken orally with water, preferably with food to minimize gastrointestinal discomfort. Dosage and dosing schedules should be individualized based on clinical response and tolerability, with regular follow-up appointments recommended for optimal management of symptoms.

Dosage:

The recommended starting dose of Paliperidone for adults with schizophrenia is typically 6 mg once daily. Some patients may require a lower starting dose of 3mg once daily, with gradual titration based on individual response and tolerability. Maintenance therapy may involve doses ranging from 3mg to 12 mg once daily, tailored to the patient’s clinical status and treatment history.

Pharmacokinetics:

Paliperidone is the active metabolite of risperidone, formed via hydrolysis of the parent compound. Following oral administration, Paliperidone is rapidly absorbed, with peak plasma concentrations attained within 4 to 8 hours. Extensively metabolized in the liver, primarily via oxidative pathways, Paliperidone has a half-life of approximately 23 hours, allowing for once-daily dosing.

Pharmacodynamics:

As an atypical antipsychotic, Paliperidone exerts its therapeutic effects by blocking dopamine D2 and serotonin 5-HT2 receptors in the brain. By normalizing neurotransmitter signaling pathways, Paliperidone effectively reduces the severity of psychotic symptoms associated with schizophrenia and related disorders.

Side Effects:

Common side effects of Paliperidone may include somnolence, extrapyramidal symptoms, weight gain, and metabolic abnormalities. Less common but potentially serious adverse effects include orthostatic hypotension, QT prolongation, and neuroleptic malignant syndrome. Regular monitoring for signs of adverse reactions is essential, with appropriate adjustments to therapy as necessary.

Trust in the efficacy and safety of Paliperidone Tablets from PharmAlliance International Labs Private Limited. Whether managing schizophrenia or related psychotic disorders, our product offers a reliable solution to help patients achieve symptom control and improve their quality of life. For more information, please visit our website or consult your healthcare provider.